ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.89
+0.68%Oct 1, 2026, 11:30 UTC
Artiva Biotherapeutics presented updated clinical data for its AlloNK® therapy in Sjögren's disease at the 17th International Symposium on Sjögren's Disease (ISSjD 2026).
Source:Sep 23, 2026, 11:30 UTC
Artiva Biotherapeutics announced that updated clinical data for its AlloNK (AB-101) allogeneic NK cell therapy combined with rituximab in Sjögren's disease patients will be presented orally at the 17th International Symposium on Sjögren's Disease in Paris.
Source:Sep 11, 2026, 20:27 UTC
Artiva Biotherapeutics, Inc. elected Brian Daniels, M.D. and Laura Stoppel, Ph.D. as Class II directors effective September 8, 2026.
Jun 8, 2026, 10:30 UTC
The U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Artiva Biotherapeutics' AlloNK plus rituximab for refractory rheumatoid arthritis.
Source: